Kashiv Biosciences has agreed to be acquired by Amneal Pharmaceuticals, aiming to create a fully integrated global leader in biosimilars.

The transaction will integrate both parties’ advantageous resources in R&D, production, and commercialization to form a strong synergy. Through this strategic merger, the new entity will possess capabilities spanning the entire value chain of biosimilars—from early-stage development to global marketing—further strengthening its competitiveness in the rapidly growing biopharmaceutical market. Market observers believe this integration will reshape the industry landscape and provide patients with more affordable, high-quality treatment options. The financial details and specific timeline of the transaction have not yet been disclosed, and completion is expected after the customary closing conditions are met. Both management teams are optimistic about the merged entity’s prospects, believing this will accelerate access to innovative therapies and create long-term sustainable value.